Skip to Content
About Abbott
Contact
United States | eng
Country Language
CARDIOVASCULAR
United States | eng
Country Language

MOMENTUM 3 Trial

Publications and Presentations

Momentum 3 2-Year Outcomes

MOMENTUM 3 2-Year Outcomes

366 Patients Followed for Two Years

Two-Year Primary Outcomes in the MOMENTUM 3 Long-Term Cohort

 

Mehra, M.R., Goldstein, D.J., Uriel, N., Cleveland, J.C., Yuzefpolskaya, M., Salerno, C., …, Naka, Y., for the MOMENTUM 3 Investigators. (2018). Two-Year Outcomes with a Magnetically Levitated Cardiac Pump in Heart Failure. N Engl J Med, 378(15), 1386-95. https://www.doi.org/10.1056/NEJMoa1800866

The data from the two-year MOMENTUM 3 trial pre-specified primary analysis demonstrates:

  • Durability of the HeartMate 3 LVAS to optimally support patients who wait for extended periods for heart transplantation or are ineligible for heart transplantation (destination therapy).
  • Clinical superiority of the HeartMate 3 LVAS when compared to the HeartMate II LVAS axial-flow pump.
  • Lowest published rates for both stroke and pump thrombosis at 2 years.
  • Lower rate of reoperation for pump malfunction in the HeartMate 3 LVAS arm.
View Article
Download Presentation
Two-Year Outcomes with a Magnetically Levitated Cardiac Pump in Heart Failure. N Engl J Med,

Healthcare Resource Use and Cost Implications in the MOMENTUM 3 Long-Term Cohort

Mehra, M.R., Salerno, C., Cleveland, J.C., Pinney, S., Yuzefpolskaya, M., Milano, C. A., ... Silvestry, S.C. (2018)Healthcare Resource Use and Cost Implications in the MOMENTUM 3 Long-Term Outcome Study: Randomized Controlled Trial of a Magnetically Levitated Cardiac Pump in Advanced Heart Failure. Circulation, 138(18), 1923-34. https://doi.org/10.1161/CIRCULATIONAHA.118.035722

In this two-year economic analysis of the MOMENTUM 3 trial, the HeartMate 3 LVAS in comparison with the HeartMate II LVAS demonstrated:

  • Reduction in rehospitalizations.
  • Reduction in hospital days spent during rehospitalizations.
  • Cost savings following discharge.
View Article
Download Presentation
Randomized Controlled Trial of a Magnetically Levitated Cardiac Pump in Advanced Heart Failure. Circulation

Comprehensive Analysis of Stroke in the MOMENTUM 3 Long-Term Cohort

 

Colombo, P.C., Mehra, M.R., Goldstein, D.J., Estep, J.D., Salerno, C., Jorde, U.P., … Horstmanshof, D.A. (2019). Comprehensive Analysis of Stroke in the Long-Term Cohort of the MOMENTUM 3 Study: A Randomized Controlled Trial of the HeartMate 3 Versus the HeartMate II Cardiac Pump. Circulation, 139 (2), 155-168. https://doi.org/10.1161/CIRCULATIONAHA.118.037231

This comprehensive stroke analysis of the long-term cohort of the MOMENTUM 3 study shows the following:

  • In patients with advanced heart failure, the use of the HeartMate 3 LVAS lowers stroke rates when compared with the HeartMate II LVAS pump.
  • The occurrence of stroke of any type or any functional severity is predictive of a poor two-year clinical outcome.
View Article
Download Presentation
A Randomized Controlled Trial of the HeartMate 3 Versus the HeartMate II Cardiac Pump. Circulation

MAT-2006846 v5.0

POLICIES & ADVISORIES
HEALTHCARE PROFESSIONALS
PATIENTS & CAREGIVERS
abbott logo

CAUTION: These products are intended for use by or under the direction of a physician. Prior to use, reference the Instructions for Use, inside the product carton (when available) or online for more detailed information on Indications, Contraindications, Warnings, Precautions and Adverse Events.

Illustrations are artist's representations only and should not be considered as engineering drawings or photographs.

Unless otherwise specified, all product names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company. ™ Indicates a trademark of the Abbott group of companies. ‡ Indicates a third party trademark, which is property of its respective owner.

© 2024 Abbott. All Rights Reserved.

MAT-1900882 v13.0